Prismic Pharmaceuticals is a commercial-stage, specialty pharmaceutical company focused on the development of innovative, proprietary, prescription medical foods with IP protection, for broad-based commercialization in the United States and internationally by Prismic and selected commercial partners.
Medical foods are classified by the Orphan Drug Act of 1983, section 5(b), and are exempt from approval by or notification to the FDA. Key requirements for a medical food are a) the product’s active ingredient(s) is or are GRAS (Generally Recognized As Safe), a specific designation achieved either by reference to the FDA’s list of GRAS ingredients or through self-affirmation based on the written attestation of an expert committee; b) meets the distinct nutritional requirements of a disease or medical condition which, based on recognized scientific principles, have been established by medical evaluation; and c) is administered under the supervision of a physician. Such products are not for purchase by the general public.
Prismic focusses on commonly occurring medical conditions, and particularly those associated with the aging population where inflammation is a key underlying factor, and where current therapies are incomplete.
Our areas of therapeutic focus are psychiatric disorders, Chronic Kidney Disease (CKD), central and peripheral nervous system disorders (CNS and PNS), and Chronic Pain. These are large, commercially attractive markets.
Depression, Bi-Polar Disease and Schizophrenia affect over 30 million people in the US each year and the combined annual spending on anti-psychotic and anti-depressant medications exceeds $29 billion.
CKD affects an estimated 26 million people in the USA, with an increasing prevalence worldwide estimated at between 8% and 16% of the population. The cost to Medicare alone in the USA is estimated at $57.5 billion annually.
Prismic Pharmaceuticals is unique in that it is committed to minimizing the number of direct employees, and maximizing the use of technology in order to achieve exceptional levels of productivity and profitability. To this end, the company has established partnerships with technology companies to provide highly customized applications, including live video meetings, that will allow Prismic to, cost-effectively, conduct many of its interactions with targeted physicians remotely and at the convenience of the physicians. These interactions will include key opinion leader meetings, speaker programs, medical science liaison support, and face-to-face, onscreen educational and sales/detailing sessions.
Prismic is headquartered in Scottsdale, Arizona, USA.